Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Kobe-city, Japan Clinical Trials

A listing of Kobe-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)

The objective of the Clinical Experience Investigation (CEI) is to collect following data to characterise safety and efficacy of LYMPARZA Tablets 100mg and 150mg (LYMPARZA) in usual post-marketing use. Development of adverse drug reactions (ADRs) Factors which may affect safety and efficacy of LYMPARZA Development of adverse drug reactions (ADRs) ...

Phase N/A

0.71 miles

Learn More »

The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography

The investigators investigate to evaluate the efficacy of alirocumab for vulnerable plaque. The investigators enrolled the patient with standard statin therapy who were detected vulnerable plaque by optical coherence tomography, and categorized into two group; the patients with alirocumab and rosuvastatin were categorized alirocumab therapy group, and the patients with ...

Phase

1.3 miles

Learn More »

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

To examine the clinial efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patinets, we enroll ALS patients diagnosed by revised-Awaji-El Escorial criteria within 12 months after the clinical onset. First they are followed for 12 ...

Phase

2.58 miles

Learn More »

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial response [PR] defined by National Institutes of Health [NIH] consensus development project criteria [2014]).

Phase

2.58 miles

Learn More »